 |
| |
|
|
The
Central Drug Research Institute
(CDRI) was
established under the Council
of Scientific & Industrial
Research, an autonomous registered
Society of the federal government,
as a centre dedicated to drug
research.
|
|
|
|
|
|
|
| |
|
|
| |
|
| FACILITIES
AVAILABLE |
 |
|
|
| |
|
|
| |
REPRODUCTIVE
HEALTH RESEARCH |
|
|
•
|
Thermal
Cycler |
•
|
Spectrofluorometer |
|
•
|
Gel
Documentation System |
•
|
Digital
Image analysis system |
|
•
|
ELISA Microplate Reader |
•
|
Fluorescence
Microscope |
|
•
|
Computer
Assisted Semen Analyzer (CASA) |
•
|
Ultra
Freezer (-80°C) |
|
•
|
Ultracentrifuge |
|
Radiation
Counters |
|
|
|
|
•
|
In vitro screening
against P. falciparum strains |
|
•
|
In vivo screening
for blood schizontocidal, causal prophylactic
and gametocytocidal activities in rodent
malaria models |
|
•
|
Dose response
studies for blood schizontocidal, causal
prophylactic anti- relapse and gametocytocidal
activities in simian malaria models. |
|
•
|
Models to
study drug response in combination |
|
|
|
| Cloning
and expression in prokaryotes. |
|
BACTEC |
| Facilities
for ultra and high speed centrifugation |
Luminometer,
Fluorimeter and Spectrophotometer |
| Protein
purification |
Electrophoretic
separation of nucleic acids and proteins. |
| Tissue
culture facility. |
Screening
of anti-tubercular, anti-microbial and
anti-fungal compounds in vitro, |
| DNA
sequencing facility (central) |
ex-vivo
and in vivo. |
| Microarray
facility (central) |
Antibodies
and cytokine assays. |
| Proteome
facility (central) |
Synthesis
of new chemical entities (NCE) |
|
|
|
|
•
|
High
Performance Thin Layer Chromatography
(HPTLC |
|
•
|
Differential
Scanning Calorimetry |
|
•
|
Particle
Size Analyzer |
|
•
|
High
Performance Preparative Liquid Chromatography |
|
•
|
High
Performance Liquid Chromatography |
|
|
|
|
•
|
Protocol development
for phase I to phase IV clinical trials
and human pharmacokinetic studies. |
|
•
|
Capabilities
to undertake phase I clinical trials
in healthy human volunteers. |
|
•
|
Effective
coordination and management of phase
II & III clinical trials for efficacy
evaluation in specified patient population.
(CPU, KGMC, Lucknow and Seth G.S. Medical
College, Bombay are two extension units
of the department providing valuable
support for phase II and III clinical
trials. |
|
•
|
Infrastructure
available for phase I, II & III
data recording, retrieval and statistical
analysis. |
|
•
|
Phase IV post
marketing surveillance for ADR monitoring
and drugs surveillance in close coordination
with pharmaceutical industry and Drugs
Controller General of India. |
|
•
|
Capabilities
to formulate clinical trial reports,
dossiers on new investigational drugs
for submission to Drugs Controller General
(India) for clinical trial (phase I
to phase IV) and marketing permission. |
|
•
|
Essential
requirement for undertaking clinical
trials available in the Department |
|
•
|
Facilities
for physical examination of volunteers/patients,
laboratory investigations: Haematology,
Clinical Biochemistry, Complete Urinalysis,
Stool Examination, Platelet Aggregation
|
|
|
|
|
•
|
Fully automated
haematology analyser |
|
•
|
Fully automated
urine analyser |
|
•
|
Fully automated
chemistry analyzer |
|
•
|
Image Analysis
System |
|
•
|
Thermal Cycler |
|
•
|
Tissue slicing
system |
|
|
|
|
REGULATORY
PHARMACOKINETICS |
|
|
•
|
HPLC |
|
•
|
TLC/GC |
|
•
|
ELISA/RIA |
|
| |
|
|
|
